Navigating Antitrust Changes in the Healthcare Industry

Staying well-informed of the dynamic regulatory landscape at both the state and federal levels is crucial to the long-term success and growth of a healthcare organization. Over the past several months, agencies including the Federal Trade Commission (FTC) and the Department of Justice (DOJ) have withdrawn guidelines containing safe harbor clauses.

These modifications have a significant impact on providers' financial and clinical aspects and may cause delays in closing merger & acquisition deals. Moreover, they may result in increased scrutiny for prosecution potential under revised thresholds.

We invite you to join a panel of experts from Fenwick's Antitrust, Healthcare Regulatory and M&A practices as they offer valuable insights into the current landscape and address the following key questions:

• What strategic measures should healthcare organizations undertake in response to these antitrust law alterations?
• Which potential pitfalls should legal professionals, C-suite executives, and investors in the healthcare industry be aware of?
• What practical steps can be taken to ensure compliance with the latest regulations?

CLE credit will be available to attendees (pending approval).